163921-65-1
Chemical Structure
Azithromycin-d3
- CAS No.: 163921-65-1
- Formula:C38H69D3N2O12
- Molecular Weight:752.00
IUPAC Name: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,8,10,12,14-hexamethyl-6-(methyl-d3)-1-oxa-6-azacyclopentadecan-15-one
InChIKey: MQTOSJVFKKJCRP-DAANATKPSA-N
SMILES: C[C@H]([C@@H](O[C@@]([H])([C@@H]1O)O[C@@H](C[C@@H]1N(C)C)C)[C@](C[C@@H](C)CN2C([2H])([2H])[2H])(C)O)[C@H](O[C@@]([H])(C[C@]3(OC)C)O[C@H]([C@@H]3O)C)[C@@H](C)C(O[C@@H]([C@@](O)([C@@H]([C@H]2C)O)C)CC)=O
Biological Activity: Azithromycin-d3 is the deuterium labeled Azithromycin. Azithromycin (CP-62993) is a macrolide antibiotic useful for the treatment of a number of bacterial infections[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Azithromycin-d3 | 98.0% | Azithromycin-d3 is the deuterium labeled Azithromycin. Azithromycin (CP-62993) is a macrolide antibiotic useful for the treatment of a number of bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azithromycin-13C,d3-1 | Azithromycin-13C,d3-1 is a deuterated labeled Azithromycin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azithromycin-d5 | Azithromycin-d5 (CP-62993-d5) is the deuterium labeled Azithromycin (CP-62993) (HY-17506). Azithromycin is a macrolide antibiotic useful for thestudy of a number of bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azithromycin-13C,d3 | 99.90% | Azithromycin-13C,d3 is the deuterium and 13C labeled Azithromycin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Azithromycin | 98.0% | Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18. [Content Brief]
